Director/PDMR Shareholding

RNS Number : 5384M
Advanced Medical Solutions Grp PLC
11 May 2020


11 May 2020

  Advanced Medical Solutions Group plc

(“AMS”, the “Company” or the “Group”)

 

  Director/PDMR Shareholding

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, announces that the Trust which manages the Deferred Share Bonus Plan (“DSB”) on behalf of the employees of AMS has purchased ordinary shares of 5 pence each (“Ordinary Shares”) on 5 May 2020, at a price of 244.97p on behalf of Chris Meredith and Eddie Johnson, who are both Directors and PDMRs, as part of the DSB and, under the terms of the DSB, these shares will be held in trust on their behalf.

 

The announcement made on 6 April 2020 explained that Chris Meredith and Eddie Johnson were selling shares, the proceeds of which would be used to purchase shares in the DSB. The purchases outlined above complete that process.

 

Following these transactions the beneficial ownership of Chris Meredith and Eddie Johnson are as follows:

 

Director/PDMR

Date purchased

Shares purchased (through DSB)

Resultant holding

% of issued share capital

Chris Meredith

Chief Executive Officer

5 May 2020

16,739

1,511,550

0.7%

Eddie Johnson

Chief Financial Officer

5 May 2020

10,564

67,967

0.032%

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Chris Meredith

2.

Reason for the notification

a)

Position/status: Director/PDMR

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transactions:

· Purchase of 16,739 Ordinary Shares as part of the Deferred Share Bonus Plan on 5 May 2020 at a price of 244.97p

c)

Price(s) and volume(s):

Sale of shares:

Price(s)

Volume(s)

n/a

n/a

d)

Aggregated information: (Relates to those shares sold only)

Aggregated volume: n/a

Aggregated price: n/a

e)

Date of the transaction: 05/05/2020

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Eddie Johnson

2.

Reason for the notification

a)

Position/status: Director/PDMR

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transactions:

· Purchase of 10,564 Ordinary Shares as part of the Deferred Share Bonus Plan on 5 May 2020 at a price of 244.97p

c)

Price(s) and volume(s):

Sale of shares:

Price(s)

Volume(s)

n/a

n/a

d)

Aggregated information: (Relates to those shares sold only)

Aggregated volume: n/a

Aggregated price: n/a

e)

Date of the transaction: 05/05/2020

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

-End –

 

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer




Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Mary-Jane Elliott / Matthew Neal / Olivia Manser

AMS@consilium-comms.com



Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Daniel Adams / Patrick Robb / Gary Clarence


 

About Advanced Medical Solutions Group plc

 

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and woundcare markets, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, and internal fixation devices, which it markets under its brands LiquiBand®, RESORBA®, and LiquiBandFix8®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. In 2019, the Group made two acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; and Biomatlante, an established developer and manufacturer of innovative surgical biomaterial technologies based in France.

 

AMS’s products, manufactured in the UK, Germany, France, the Netherlands, and the Czech Republic, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Germany, France and Israel. Established in 1991, the Group has approximately 700 employees. For more information, please see www.admedsol.com.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHBSGDUIUBDGGB